FDA accepts Verrica Pharma’s NDA for molluscum contagiosum drug

The FDA accepted Verrica Pharmaceuticals’ (NASDAQ:VRCA) NDA for its molluscum contagiosum drug candidate, VP-102, assigning a PDUFA date of July 13, 2020.

VP-102 is a topical cantharidin solution designed to treat molluscum contagiosum, a viral skin infection.

Verrica’s NDA is based on positive results from two Phase 3 trials, both of which demonstrated VP-102’s superior efficacy in clearing all treatable lesions, compared with placebo.

“There are no FDA-approved treatments currently available to patients diagnosed with molluscum, the majority of whom are children, leaving caregivers to choose between a wait-and-see approach or treatments with unproven efficacy,” president and CEO Ted White said in a statement.

“The acceptance of this NDA for review is the next step toward bringing patients and their caregivers a safe and effective topical therapy for this common, highly contagious viral skin disease that carries a substantial social stigma,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.